NeuroMetrix Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12th, 2017
WALTHAM, Mass.–(BUSINESS WIRE)–$NURO #neurometrix–NeuroMetrix, Inc. (Nasdaq:NURO) today announced it will be a presenting
company at the 19th Annual Rodman & Renshaw Global Investment
Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is
being held on September 10-12, 2017, at Lotte New York Palace Hotel
in New York City. Shai N. Gozani, M.D., Ph.D., President and CEO
of NeuroMetrix, will provide an overview of the Company’s business
during the live presentation and will be available to participate in
one-on-one meetings with investors who are registered to attend the
conference.
The NeuroMetrix presentation is scheduled for Monday, September 11,
2017 at 11:15 AM Eastern time. A live audio webcast will be available on
the investor relations section of the corporate website, www.NeuroMetrix.com.
This webcast will be archived after the live event.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company
combining neurostimulation and digital medicine to address chronic
health conditions including chronic pain, sleep disorders, and diabetes.
The company’s lead product is Quell®, an over-the-counter
wearable therapeutic device for chronic pain. Quell is integrated into a
digital health platform that helps patients optimize their therapy and
decrease the impact of chronic pain on their quality of life. The
company also markets DPNCheck®, a rapid point-of-care test
for diabetic neuropathy, which is the most common long-term complication
of Type 2 diabetes. The company maintains an active research effort and
has several pipeline programs. The company is located in Waltham,
Massachusetts and was founded as a spinoff from the Harvard-MIT Division
of Health Sciences and Technology in 1996. For more information, please
visit NeuroMetrix.com.
Contacts
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and
Chief Financial Officer
Neurometrix.ir@neurometrix.com
